20 Publikationen in 2025
Kumulativer IF: 430.3
Mittelwert IF: 21.52

1. From bile to vessels: linking obesity to endothelial dysfunction
Kraler S, Vilahur G, Kleinbongard P
Eur Heart J; DOI: 10.1093/eurheartj/ehaf957    (Impact Factor = 35,6)

2. Angina with non-obstructive coronary arteries: haemodynamic phenotyping vs mechanistic pathophysiology
Heusch G, Kleinbongard P
Eur Heart J; 47:605-607    (Impact Factor = 35,6)

3. Importance of basic science and research training for the future generation of cardiologists
Chiva-Blanch G, Liehn E, Andreadou I, Barc J, Brundel B, Davidson S, Elliott P, Evans P, Giricz Z, Gladka M, Gollmann-Tepekoylu C, Kleinbongard P, Krieg T, Linde C, Luscher T, Guzik T, Maguy A, Mcdonagh T, Paillard M, Parma R, Pesce M, Pompilio G, Rubini M, Streckfuss-Bomeke K, Thielmann M, Tocchetti C, Van Linthout S, Vardas P, Vranckx P, Wojta J, Perrino C
Eur Heart J; DOI: 10.1093/eurheartj/ehaf738    (Impact Factor = 35,6)

4. Involvement of (trained) immunity in cardioprotection
Heusch G, Kleinbongard P
Cardiovasc Res; 121:1979-7980    (Impact Factor = 13,3)

5. Peptidylarginine deiminase 4 deficiency alleviates hypoxia/reoxygenation-induced cardiomyocyte injury
Mand M, Holthaus M, Lieder H, Kleinbongard P, Conradi L, Wahlers T, Paunel-Gorgulu A
PLoS One; DOI: 10.1371/journal.pone.0330864    (Impact Factor = 2,6)

6. Cardiovascular prevention 2024 lipid disorders: insights from the National Societies of Cardiology Journals of the European Society of Cardiology
Monsuez J-J, Gatzov P, Alfonso F
Eur Heart J; 46:3949-3951    (Impact Factor = 35,6)

7. Perspectives on Artificial Intelligence in Medical Publishing: A Survey of Medical Journal Editors
Biondi-Zoccai G, Lauretti A, Agewall S, Andres E, Audisio R, Bhatt D, Citerio G, Drezner J, Eggermont A, Erol C, Ersche K, Ferriero G, Heusch G, Indolfi C, Insel P, Lavie C, La Vecchia C, Maffulli N, Montecucco F, Moliterno D, Nattel S, O'Kane P, Oliaro E, Pelliccia A, Picard M, Pozzilli P, Quaglia F, Riha R, Sarkar R, Scicchitano P, Teboul J-L, Stahel H T, Wold L E, Booz G W
J Cardiovasc Pharmacol .; 86:374-383    (Impact Factor = 2,2)

8. Cardioprotection Through Pharmacological Activation of Sirtuin 5 in a Murine Model of Acute Myocardial Infarction
Castiello C, Efentakis P, Nikolaou P, Symeonidi L, Chania C, Barla I, Akrani I, Kostomitsopoulos N, Gikas E, Thomaidis N, Mikros E, Kleinbongard P, Fioravanti R, Zwergel C, Valente S, Mai A, Andreadou I
Drug Des Devel Ther.; 19: 5489-5505    (Impact Factor = 5,1)

9. Progress on incorporating sex as a biological variable in cardiovascular research
Lindsey M L, LeBlanc A J, Ripplinger C M, Kassiri Z, Kirk J A, Kleinbongard P, Carter J R, Brunt K R
AM J PHYSIOL-HEART C; 329:H309-H310    (Impact Factor = 4,1)

10. Vascular (dys)function in the failing heart
Liberale L, Duncker D J, Hausenloy D J, Kraler S, Bøtker H E, Podesser B K, Heusch G, Kleinbongard P
Nat Rev Cardiol; doi: 10.1038/s41569-025-01163-w    (Impact Factor = 44,2)

11. Immunometabolism in heart failure
Andreadou I, Ghigo A, Nikolaou P-E , Swirski F K, Thackeray J T, Heusch G, Vilahur G
Nat Rev Cardiol; 22:751-772    (Impact Factor = 44,2)

12. Mitochondrial targets in ischaemic heart disease and heart failure and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function
Paillard M, Abdellatif M, Andreadou I, Baer C, Bertrand L, Brundel B, Chiva-Blanch G, Davidson S, Dawson D, Di Lisa F, Evans P, Giricz Z, Hausenloy D, Kleinbongard P, Lezoualc'h F, Liehn E, Maack C, Maguy A, Murphy E, Perrino C, Pesce M, Rainer P, Streckfuss-Boemeke K, Thielmann M, Tian R, Tocchetti C, van der Velden J, Van Linthout S, Zacchigna S, Krieg T
EUR J HEART FAIL; 27:1720-1736    (Impact Factor = 10,8)

13. Ischaemic conditioning: a renaissance with wider perspectives?
Heusch G, Kleinbongard P
Eur Heart J; doi.org/10.1093/eurheartj/ehaf205    (Impact Factor = 35,6)

14. It takes more than omics to identify a cardioprotective mechanism.
Heusch G, Kleinbongard P
Cardiovasc Res; 10.1093/cvr/cvaf052    (Impact Factor = 13,3)

15. In memoriam: Ioanna Andreadou (1965-2025)
Vilahur G, Kleinbongard P, Zuurbier C
Eur Heart J; 46:1699-1701    (Impact Factor = 35,6)

16. Opportunities and challenges for the use of human samples in translational cardiovascular research: a scientific statement of the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Cardiovascular Surgery, the ESC Council on Basic Cardiovascular Science, the ESC Scientists of Tomorrow, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the Heart Failure Association of the ESC
Sean M. Davidson, Ioanna Andreadou, Charalambos Antoniades, Jozef Bartunek, Cristina Basso, Bianca J.J.M. Brundel, Robert A. Byrne, Gemma Chiva-Blanch, Paula da Costa Martins, Paul C. Evans, Henrique Girão, Zoltan Giricz, Can Gollmann-Tepeköylü, Tomasz Guzik, Mariann Gyöngyösi, Norbert Hübner, Michael Joner, Petra Kleinbongard, Thomas Krieg, Elisa Liehn, Rosalinda Madonna, Ange Maguy, Melanie Paillard, Maurizio Pesce, Steffen E. Petersen, Gabriele G. Schiattarella, Joost P.G. Sluijter, Sabine Steffens, Katrin Streckfuss-Bömeke, Matthias Thielmann, Art Tucker, Sophie Van Linthout, William Wijns, Johann Wojta, Joseph C. Wu, Cinzia Perrino
Cardiovasc Res; 10.1093/cvr/cvaf023    (Impact Factor = 13,3)

17. Reperfused Myocardial Infarction The Road to CCS Classification of Acute MI and Beyond
Dharmakumar , Kloner R, Fishbein, Heusch G, Vora K, Gropler R, Henry T, Chan S, Singh D, Jambunathan N, Subramanian R, Kreutz R, Reed G, Kovacs R, Fry E, Kalra A, Kumar A, V. Raman S
JACC Adv.; DOI: 10.1016/j.jacadv.2024.101528    (Impact Factor = 1,73)

18. The Enigmata of Cardioprotection With SGLT2 Inhibition.
Heusch G, Kleinbongard P
JACC Basic Transl Sci; 10:62-64    (Impact Factor = 7,2)

19. The spleen in ischaemic heart disease
Heusch G, Kleinbongard P
Nat Rev Cardiol; 10.1038/s41569-024-01114-x    (Impact Factor = 44,2)

20. From Ca2+ dysregulation to heart failure: β-adrenoceptor activation by RKIP postpones molecular damages and subsequent cardiac dysfunction in mice carrying mutant PLNR9C by correction of aberrant Ca2+-handling.
Brand T, Baumgarten BT, Denzinger S, Reinders Y, Kleindl M, Schanbacher C, Funk F, Gedik N, Jabbasseh M, Kleinbongard P, Dudek J, Szendroedi J, Tolstik E, Schuh K, Krüger M, Dobrev D, Cuello F, Sickmann A, Schmitt JP, Lorenz K.
Pharmacol Res; 211:107558    (Impact Factor = 10,5)